Evidence map›Paper›PMID 35953136›Full record

Observational studyJournal of the American College of Cardiology2022

Clinical Characteristics and Transplant-Free Survival Across the Spectrum of Pulmonary Vascular Disease.

Anna R Hemnes, Jane A Leopold, Milena K Radeva, Gerald J Beck, Aiden Abidov, Micheala A Aldred, John Barnard, Erika B Rosenzweig, Barry A Borlaug, Wendy K Chung and 39 more

2 registry-linked trialsOpen access · greenAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of the American College of Cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 70 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 1 pooled it
12.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02980887 active not recruitingnot on this map

Redefining Pulmonary Hypertension Through Pulmonary Vascular Disease Phenomics (PVDOMICS)

TypeobservationalSponsorThe Cleveland ClinicRan2016 to 2029Enrolled1,195ConditionsPulmonary Arterial HypertensionArmsNo Intervention
NCT04071327 recruitingnot on this map

Pulmonary Hypertension Association Registry

Typeobservational_patient_registrySponsorPulmonary Hypertension Association, Inc.Ran2015 to 2025Enrolled3,000ConditionsPulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Hypertension
3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 1 synthesis or guideline pooled it, 91 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

49 authors at 19 institutions in 2 countries.

Anna R HemnesDivision of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Electronic address: anna.r.hemnes@vumc.org.
Jane A LeopoldDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Milena K RadevaDepartment of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA.
Gerald J BeckDepartment of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA.
Aiden AbidovDivision of Cardiology, Wayne State University, Detroit, Michigan, USA.
Micheala A AldredDepartment of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
John BarnardDepartment of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA.
Erika B RosenzweigDepartment of Pediatrics and Medicine, Columbia University, New York, New York, USA.
Barry A BorlaugDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Wendy K ChungDepartment of Pediatrics, Columbia University, New York, New York, USA.
Suzy A A ComhairDepartment of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, USA.
Ankit A DesaiDepartment of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Hilary M DubrockDepartment of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Serpil C ErzurumLerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
J Emanuel FinetDepartment of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
Robert P FrantzDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Joe G N GarciaDepartment of Medicine, University of Arizona, Tucson, Arizona, USA.
Mark W GeraciDepartment of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Michael P GrayDepartment of Cardiology, The University of Sydney, Sydney, New South Wales, Australia.
Gabriele GrunigDepartment of Environmental Medicine, New York University Grossman School of Medicine, New York, New York, USA.
Paul M HassounDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Kristin B HighlandRespiratory Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Nicholas S HillDivision of Pulmonary, Critical Care, and Sleep Medicine, Tufts Medical Center, Boston, Massachusetts, USA.
Bo HuDepartment of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA.
Deborah H KwonDepartment of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
Miriam S JacobDepartment of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
Christine L JellisDepartment of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
A Brett LariveDepartment of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA.
Jason K LempelImaging Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Bradley A MaronDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Stephen C MathaiDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Kevin McCarthyRespiratory Solutions, ERT, Inc, Cleveland, Ohio, USA.
Reena MehraNeurologic and Respiratory Institutes, Cleveland Clinic, Cleveland, Ohio, USA.
Rawan NawabitPediatrics Institute, Cleveland Clinic, Cleveland, Ohio, USA.
John H NewmanDivision of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Mitchell A OlmanDepartment of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, USA.
Margaret M ParkDepartment of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
Jose A RamosRespiratory Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Rahul D RenapurkarImaging Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Franz P RischardDivision of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Arizona, Tucson, Arizona, USA.
Susan G ShererDepartment of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA.
W H Wilson TangDepartment of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
James D ThomasBluhm Cardiovascular Institute, Northwestern Medicine, Chicago, Illinois, USA.
Rebecca R VanderpoolDivision of Cardiovascular Medicine, The Ohio State University, Columbus, Ohio, USA.
Aaron B WaxmanDivision of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Jennifer D WilcoxDepartment of Cardiovascular and Metabolic Sciences, Cleveland Clinic Cleveland, Ohio, USA.
Jason X-J YuanDepartment of Medicine, University of California, San Diego, California, USA.
Evelyn M HornPerkin Heart Failure Center, Division of Cardiology, Weill Cornell Medicine, New York, New York, USA.
PVDOMICS Study Group
Cleveland Clinic · USBrigham and Women's Hospital · USMayo Clinic · USColumbia University · USIndiana University School of MedicineJohns Hopkins University · USUniversity of Arizona · USVanderbilt University Medical Center · USCleveland Clinic Lerner College of Medicine · USCornell University · USDANTE Solutions (United States) · USNew York University · USNorthwestern Medicine · USThe Ohio State University · USThe University of Sydney · AUTufts Medical Center · USUniversity of California San Diego · USUniversity of Pittsburgh · USWayne State University · US

Funding

Pulmonary Vascular Disease Phenomics Program (PVDOMICS) Data Coordinating CenterU01HL125177 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI BECK, GERALD J, ERZURUM, SERPIL C. · 2014 to 2020
$20.0M
Genomics of Pulmonary Vascular DiseaseR35HL140019 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI ALDRED, MICHEALA A · 2018 to 2024
$5.6M
Impact of Low Flow Nocturnal Oxygen Therapy On Hospital Readmission/Mortalityin Patients with Heart Failure and Central Sleep Apneal (LOFT-HF)UH3HL140144 · NHLBI · OHIO STATE UNIVERSITY · PI ABRAHAM, WILLIAM TOBER · 2019 to 2020
$5.5M
Genomic and Circulating Predictors of PAH responseR01HL142720 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Anna R Hemnes · 2019 to 2026
$5.0M
Novel Involvement of NAMPT and TLR4 in PAH Vascular RemodelingR01HL141387 · NHLBI · UNIVERSITY OF FLORIDA · PI Joe G. N. Garcia, Ayako Makino · 2019 to 2026
$3.8M
Network Medicine and Systems Pharmacology to Advance Precision Medicine in Combined Pulmonary HypertensionR01HL163960 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Evan L Brittain, Anna R Hemnes · 2022 to 2026
$3.4M
Pathogenic Role of IL-18 in Sickle Cell Cardiomyopathy and Inducible Ventricular TachycardiaR01HL136603 · NHLBI · UNIVERSITY OF ARIZONA · PI DESAI, ANKIT A · 2017 to 2021
$2.4M
TRPV4-PI3K Axis Mediates Pulmonary and Cardiac FibrosisR01HL133721 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI OLMAN, MITCHELL ALAN, PRASAD, SATHYAMANGLA V · 2017 to 2020
$2.2M
Intergrated Endothelial Phenotyping to Redefine Pulmonary HypertensionU01HL125215 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI LEOPOLD, JANE A, WAXMAN, AARON B · 2014 to 2018
$1.7M
Profibrotic Mechanisms of the TRPV4-PI3K-gamma Protein ComplexR01HL158746 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI OLMAN, MITCHELL ALAN · 2021 to 2024
$1.6M
PVDOMICS Defining the Future Fingerprints of Pulmonary Vascular DiseaseU01HL125218 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BERMAN-ROSENZWEIG, ERIKA S., HORN, EVELYN · 2014 to 2018
$1.6M
Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics: Clinical Centers (CC) (U01).U01HL125205 · NHLBI · MAYO CLINIC ROCHESTER · PI FRANTZ, ROBERT PAUL · 2014 to 2018
$1.5M
NHLBI NIH HHS R01 HL133721NHLBI NIH HHS R01 HL136603NHLBI NIH HHS R01 HL141387NHLBI NIH HHS R01 HL142720NHLBI NIH HHS R01 HL158746NHLBI NIH HHS R01 HL163960NHLBI NIH HHS R35 HL140019NHLBI NIH HHS U01 HL125175NHLBI NIH HHS U01 HL125177NHLBI NIH HHS U01 HL125205NHLBI NIH HHS U01 HL125208NHLBI NIH HHS U01 HL125212NHLBI NIH HHS U01 HL125215NHLBI NIH HHS U01 HL125218NHLBI NIH HHS UH3 HL140144
6 · The paper itself

Abstract

backgroundPVDOMICS (Pulmonary Vascular Disease Phenomics) is a precision medicine initiative to characterize pulmonary vascular disease (PVD) using deep phenotyping. PVDOMICS tests the hypothesis that integration of clinical metrics with omic measures will enhance understanding of PVD and facilitate an updated PVD classification.

objectivesThe purpose of this study was to describe clinical characteristics and transplant-free survival in the PVDOMICS cohort.

methodsSubjects with World Symposium Pulmonary Hypertension (WSPH) group 1-5 PH, disease comparators with similar underlying diseases and mild or no PH and healthy control subjects enrolled in a cross-sectional study. PH groups, comparators were compared using standard statistical tests including log-rank tests for comparing time to transplant or death.

resultsA total of 1,193 subjects were included. Multiple WSPH groups were identified in 38.9% of PH subjects. Nocturnal desaturation was more frequently observed in groups 1, 3, and 4 PH vs comparators. A total of 50.2% of group 1 PH subjects had ground glass opacities on chest computed tomography. Diffusing capacity for carbon monoxide was significantly lower in groups 1-3 PH than their respective comparators. Right atrial volume index was higher in WSPH groups 1-4 than comparators. A total of 110 participants had a mean pulmonary artery pressure of 21-24 mm Hg. Transplant-free survival was poorest in group 3 PH.

conclusionsPVDOMICS enrolled subjects across the spectrum of PVD, including mild and mixed etiology PH. Novel findings include low diffusing capacity for carbon monoxide and enlarged right atrial volume index as shared features of groups 1-3 and 1-4 PH, respectively; unexpected, frequent presence of ground glass opacities on computed tomography; and sleep alterations in group 1 PH, and poorest survival in group 3 PH. PVDOMICS will facilitate a new understanding of PVD and refine the current PVD classification. (Pulmonary Vascular Disease Phenomics Program PVDOMICS [PVDOMICS]; NCT02980887).

Indexed as

Hypertension, PulmonaryVascular DiseasesCarbon MonoxideCross-Sectional StudiesHumansPulmonary CirculationCarbon Monoxidephenotypingpulmonary hypertension

Identifiers

PMID35953136
PMCPMC9897285
OpenAlexW4290720543

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.